SUMATRIPTAN
Generic: SUMATRIPTAN
Baxter Healthcare CorporationManufacturer
SUBCUTANEOUSRoute
SUMATRIPTAN SUCCINATEActive Substance
2023-01-19Original Approval
SUMATRIPTAN is FDA application ANDA207101, sponsored by BAXTER HLTHCARE CORP. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.
Recalls
Class II2022-04-13
Sumatriptan Succinate Tablets, 100 mg, 9 (1 x 9) Unit-of- use tablets box, Rx only, MFG: Sun Pharmaceuticals, NDC 62756-cGMP deviations: Temperature abuse
Class II2019-12-26
Sumatriptan Succinate Tablets, 50 mg, packaged in a) 9 (1x9) Unit-of use blister card (NDC 62756-521-69) and b) 100 counFailed Impurities/Degradation Specifications; out-of-specification results obtained for related subs
Top Reported Reactions
1
DRUG INEFFECTIVE
2,863 reports
2
HEADACHE
2,206 reports
3
MIGRAINE
1,855 reports
4
NAUSEA
1,809 reports
5
FATIGUE
1,521 reports
6
OFF LABEL USE
1,221 reports
7
DIZZINESS
1,212 reports
8
PAIN
1,198 reports
9
PRODUCT DOSE OMISSION ISSUE
1,026 reports
10
VOMITING
970 reports